RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Acorda Therapeutics Stock

Acorda Therapeutics Market capitalization 2025

Acorda Therapeutics Market capitalization

16,767 USD

Ticker

ACOR

ISIN

US00484M6012

WKN

A0BK80

In 2025, Acorda Therapeutics's market cap stood at 16,767 USD, a -99.89% increase from the 15.91 M USD market cap in the previous year.

The Acorda Therapeutics Market capitalization history

YEARMarket Capitalization (undefined USD)
20230.02
20220.02
20210.05
20200.05
20190.38
20181.13
20171.03
20161.27
20151.67
20141.62
20131.19
20120.89
20110.9
20101.14
20090.85
20080.84
20070.47
20060.19
2005-
2004-

Acorda Therapeutics Aktienanalyse

What does Acorda Therapeutics do?

Acorda Therapeutics Inc. is a US-based biopharmaceutical company that specializes in researching, developing, and marketing therapeutics for severe neurological diseases. The company was founded in 1995 by Ron Cohen and is headquartered in Ardsley, New York. Acorda Therapeutics started as a small company with few employees and one product, Zanaflex Capsules, a muscle relaxant used for spastic conditions. The company expanded its product portfolio through acquisitions, such as the acquisition of Neuronetrix Solutions, Inc., a company specialized in diagnosing Alzheimer's and other cognitive impairments. Acorda Therapeutics has a business model focused on research and development activities and has formed partnerships with industry experts, academic institutions, and healthcare facilities to support its research efforts. The company has a strong focus on neurology and has expertise in developing protein and antibody-based medications for neurological diseases. Acorda Therapeutics' goal is to meet the needs of patients with severe neurological diseases and develop innovative therapeutics that provide real clinical benefits. The company's main products are Ampyra, an oral medication for improving walking ability in patients with multiple sclerosis, and Zanaflex Capsules, used to treat spastic conditions. Acorda Therapeutics has also developed Inbrija, an inhaled levodopa for treating off-episodes in patients with Parkinson's disease. In addition to medications, the company has developed diagnostic and monitoring devices, such as a device for monitoring vagus nerve stimulation in epilepsy patients, in partnership with Medtronic. Acorda Therapeutics has made significant contributions to the treatment of neurological diseases and has a track record of success in developing collaborative therapies and diagnostic products. While there is still much work to be done, there is hope that continued research and development of new and innovative therapeutics can improve the quality of life for millions of people suffering from severe neurological diseases. Acorda Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Acorda Therapeutics's Market Capitalization

Acorda Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Acorda Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Acorda Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Acorda Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Acorda Therapeutics stock

What is the current Acorda Therapeutics market capitalization?

The current market capitalization of Acorda Therapeutics is 16,767 USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Acorda Therapeutics.

How has the market capitalization of Acorda Therapeutics developed in recent years?

The market capitalization of Acorda Therapeutics has increased/decreased by -99.89% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Acorda Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Acorda Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Acorda Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Acorda Therapeutics pay?

Over the past 12 months, Acorda Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acorda Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Acorda Therapeutics?

The current dividend yield of Acorda Therapeutics is .

When does Acorda Therapeutics pay dividends?

Acorda Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acorda Therapeutics?

Acorda Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Acorda Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acorda Therapeutics located?

Acorda Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acorda Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acorda Therapeutics from 2/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/7/2025.

When did Acorda Therapeutics pay the last dividend?

The last dividend was paid out on 2/7/2025.

What was the dividend of Acorda Therapeutics in the year 2024?

In the year 2024, Acorda Therapeutics distributed 0 USD as dividends.

In which currency does Acorda Therapeutics pay out the dividend?

The dividends of Acorda Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Acorda Therapeutics

Our stock analysis for Acorda Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acorda Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.